Valence8 US’s Keros Therapeutics KROS Stock Holding History

Valence8 US’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,025	Closed	-$466K	–	40
2024 Q3	$466K	Buy	+8,025	New	+$396K	0.19%	24

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Valence8 US's KROS Position: Q4 2024 in Review

Valence8 US sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 8,025 shares — an estimated $466K sold.

Valence8 US first reported a position in KROS in Q3 2024 and held it in 1 quarter. The position peaked at $466K in Q3 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

Valence8 US reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 8,025 Keros Therapeutics shares in Q4 2024, an estimated $466K.
Valence8 US first reported a position in Keros Therapeutics in Q3 2024 and held it in 1 quarter.
Valence8 US's Keros Therapeutics position peaked at $466K in Q3 2024.
161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.